![](https://endpts.com/wp-content/uploads/2020/10/David-Ricks-Lilly-tile-AP-scaled.jpg)
David Ricks, Eli Lilly CEO (Evan Vucci/AP Images)
Eli Lilly: As donanemab filing approaches, execs 'even more confident' in data package
Eli Lilly had a strong Q2, but unsurprisingly analysts don’t want to talk much about drugs already approved — their eyes are set firmly on Alzheimer’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.